M acular edema (ME) is the major cause of vision loss in eyes with branch retinal vein occlusion (BRVO).
1 Intravitreal bevacizumab (IVB) has been used to treat ME in eyes with BRVO and has yielded promising results.
2 Intravitreal bevacizumab has been used both in monthly injection regimens and on a pro re nata (PRN) basis. [3] [4] [5] [6] [7] However, a certain proportion of BRVO patients do not regain vision even after resolution of ME. 1, 8 Various studies have attempted to answer this question and have established spectral domain optical coherence tomography (SD-OCT) predictors to determine the prognosis of eyes with ME due to BRVO. 1, 8 Integrity of the ellipsoid zone (EZ) and external limiting membrane (ELM) at baseline are 2 such markers that have been associated with better final visual outcome.
1 Foveal bulge (FB) is another novel marker used to predict the visual outcome of BRVO. Foveal bulge is the site at the base of fovea that has maximum cone density. Its presence after resolution of ME has been associated with better visual outcomes in BRVO.
materials and methods
This was a retrospective review of medical records of consecutive patients with BRVO presenting at a tertiary care center in eastern India between January 2013 and December 2013. The study was approved by the institutional review board and it followed the tenets of the Declaration of Helsinki. Treatment-naive patients with disease onset within the past 3 months were included in the study. Exclusion criteria were as follows: (1) intraocular surgery, including cataract extraction and any intravitreal injection before the treatment; (2) laser treatments, including panretinal photocoagulation, posterior capsulotomy, or grid macular photocoagulation before the treatment; or (3) the presence of co-morbid retinal pathologies like diabetic retinopathy and age-related macular degeneration.
Age, sex, and laterality were noted from the medical records. Best-corrected visual acuity (BCVA) was noted with Snellen chart and was converted to the logarithm of the minimum angle of resolution (logMAR) scale. Anterior segment examination with slit lamp, fundus examination with indirect ophthalmoscope, and slit lamp biomicroscopy were performed Branch retinal vein occlusion is an acute event with a sudden explosion of intravitreal vascular endothelial growth factor (VEGF). The levels of VEGF in aqueous humor correlate strongly with the degree of ME in BRVO patients. 9 However, in day-to-day clinical practice it is not possible to measure actual VEGF levels in every patient. Initial quantitative OCT-based reduction of central foveal thickness (CFT) in response to anti-VEGF may provide a clue to the VEGF levels and act as a prognostic indicator.
The response to anti-VEGF at 3 months from baseline after monthly injections was examined as a predictor of visual outcome in BRVO patients. 10 This study evaluated the predictive ability of CFT reduction at 1 month after the first injection. Our study aimed to utilize various SD-OCT parameters such as the integrity of the EZ, ELM, and FB and combine them with 1-month reduction in CFT after IVB to provide a prognostic tool for final visual outcome in eyes with ME due to BRVO.
at all visits. Optical coherence tomography was performed using Topcon 3D 2000 (Topcon Medical Systems, Oakland, New Jersey) at each visit to assess the response to treatment. Horizontal scans closest to the fovea were evaluated for study purposes; SD-OCT images of minimum image quality 45 or above were included in the study. All the scans were evaluated by an experienced retina specialist (A.G.). In case of doubt, opinion was sought from another retina specialist (D.P.C.). Consensus opinions of both specialists were evaluated for study purposes. The CFT was measured as the distance between the internal limiting membrane and the outer border of the retinal pigment epithelium at the central fovea. The distance was measured manually for each patient. The ELM was identified as the hyperreflective band after the outer nuclear layer. A second hyperreflective band after the ELM representing the interface between inner and outer segments of the photoreceptors was designated as the EZ. The integrity of the EZ and ELM were evaluated within 500 µm from the center of the fovea in a horizontal direction on each OCT image. Other OCT features like subretinal fluid (SRF), cystoid macular edema (CME), diffuse retinal thickening (DRT), and epiretinal membrane (ERM) were also evaluated. The EZ was assessed to look for bulging at the center of the fovea: the foveal bulge (FB). Eyes were classified into those with FB and those without FB. At each visit, OCT was done and all these parameters were evaluated.
All patients with ME due to BRVO with CFT greater than 300 µm received intravitreal bevacizumab 1.25 mg (Avastin; Genentech, California) at baseline. This was followed by repeat intravitreal bevacizumab injections on a PRN basis. Retreatment criterion was persistence or recurrence of macular edema denoted by CFT more than 300 µm at monthly follow-up. Patients with persistent macular edema were eligible for grid laser photocoagulation as per the treating clinician's discretion, only after the patient had received at least 3 anti-VEGF injections. Favorable anatomical outcome was defined as dry macula with no ME at final follow-up. Favorable functional outcome was defined as BCVA greater than 20/40.
Statistical analysis was done using SPSS Version 18 (SPSS Inc, Chicago, Illinois). All values are presented as the means ± standard deviations. A t test was used for quantitative variables and χ 2 test for qualitative variables. In this study, a P value less than 0.05 was considered significant. results We evaluated 60 eyes of 60 patients with BRVO. All patients had unilateral BRVO. Baseline demographic and OCT features are detailed in Table 1 . Forty-four of our patients were male, whereas 16 were female. The average age of the patients was 56 ± 11.51 years. Mean BCVA at presentation was 0.50 logMAR units and mean final BCVA was 0.32 logMAR units. There was significant improvement in BCVA after treatment (P = 0.01; paired t test). Mean CFT at baseline was 597 µm and mean final CFT was 290 µm. This difference was significant (P = 0.01; paired t test). The mean number of injections given to each patient was 2.25 ± 1.09. Adjuvant rescue macular laser was done in 9 (15%) eyes. At presentation, 27 (45%) patients had CME with SRF, 23 (38.3%) had CME, 2 (3.3%) had only SRF, 6 (10%) had DRT, and 2 (3.3%) had CME with ERM. No treatment-related complications like endophthalmitis or retinal detachment were noted in the study eyes.
The primary goal of the study was to find the predictive ability of the quantitative response after the first anti-VEGF injection with respect to the final outcome. Patients were divided into 2 groups based on OCT-measured reduction in CFT after the first injection (group A, ≤25% reduction; group B, >25% reduction). There were 23 (38.3%) and 37 (61.6%) patients in groups A and B, respectively. The clinical characteristics of patients in these 2 groups are shown in Table 2 . There was no significant difference between these groups in terms of presenting age, duration of follow-up, number of injections, initial BCVA, or initial CFT. At final follow-up patients in group B had a significantly better mean BCVA as compared with group A (0.25 logMAR vs 0.46 log MAR, P = 0.03; t test). There were significantly more patients in group B who achieved a dry macula at final follow-up as compared with group A (28 patients vs 9 patients, P = 0.005; t test). Similarly, significantly more patients in group B achieved BCVA of at least 20/40 at final follow-up as compared with group A (28 patients vs 9 patients, P = 0.005; t test).
Based on final visual outcome, we divided the patients into 2 groups: group 1, BCVA greater than 20/40; group 2, BCVA less than 20/40. There were 37 (61.6%) patients in group 1 and 23 (38.3%) patients in group 2. The clinical characteristics of patients in these 2 groups are shown in Table 3 . Demographic data and OCT microstructural data was compared between the 2 groups at the first visit, 1 month after the first injection, and at final follow-up (Figs. 1, 2) . There was no significant difference in presenting age, follow-up duration, mean presenting BCVA, mean presenting CFT, or mean number of injections between these 2 groups. Analysis of OCT data at the initial visit revealed that the ELM was intact in 12 (32.4%) and 6 (26.1%) patients in groups 1 and 2, respectively. The difference was not significant. In the rest of the patients in either group, the ELM was not seen or was not intact. Similarly, at the initial visit the EZ layer was intact in 11 (29.7%) and 9 DM indicates diabetes mellitus; HTN, hypertension; NSD, neurosensory detachment; OD, right eye; OS, left eye.
(39.1%) patients, respectively, in groups 1 and 2. Foveal bulge was intact in 2 (5.4%) and 0 patients, respectively, in groups 1 and 2. The difference was not significant for both ELM and EZ. In the rest of the patients in either group, the EZ and FB were not seen or were not intact.
Patients' clinical details, including OCT data, were reviewed 1 month after the first injection. At this visit the ELM was intact in 27 (73%) and 5 (21.7%) patients in groups 1 and 2, respectively. The difference was significant (P = 0.001, χ 2 test). The EZ was intact in 28 (75.7%) and 11 (47.8%) patients, respectively, in groups 1 and 2. This difference was significant (P = 0.02, χ 2 test). The FB was intact in 12 (32.4%) and 2 (8.7%) patients, respectively, in groups 1 and 2. This difference was significant (P = 0.03, χ 2 test). At the final visit, the ELM was intact in 24 (64.8%) and 8 (34.7%) patients in groups 1 and 2, respectively. The difference was significant (P = 0.02, χ 2 test). Similarly, the EZ was intact in 25 (67.5%) and 9 (39.1%) patients, respectively, in groups 1 and 2. The difference was significant (P = 0.03, χ 2 test). The FB was intact in 15 (40.5%) and 1 (4.3%) patients in groups 1 and 2, respectively. The difference was significant (P = 0.002, χ 2 test). discussion Intravitreal bevacizumab has been noted to be effective in the management of ME due to BRVO in both monthly injection and PRN injection schedules.
3-7 However, resolution of ME does not invariably lead to improvement of vision in these eyes. Various SD-OCT parameters have been studied to predict the resolution of ME and improvement of vision in BRVO patients. 1, 8 Intact ELM and EZ within 500 µm from the center of the fovea and presence of FB at the center of the fovea at final follow-up are considered to be predictors of resolution of ME and better visual outcome. 1, 8 However, there remains a possibility of nonvisualization of these structures at the first visit in eyes with BRVO due to overlying retinal hemorrhages.
1 Our study noted the integrity of these structures on SD-OCT at baseline and 1 month after the first IVB injection, when retinal hemorrhages start to clear over the foveal region. In addition, our study also tried to find a correlation between the response to the first IVB injection in terms of percent reduction in CFT and resolution of ME and visual outcome at the final visit.
In our patients with BRVO, intact ELM and EZ at baseline did not predict resolution of ME at final follow-up. Neither did they predict a better visual outcome in these eyes. This is in contrast to a study by Kang et al, 1 who reported that intact EZ and ELM at baseline were predictors of good visual outcome, in that order. Further, we noted that when assessed at 1 month after IVB, intact ELM, EZ layer, and FB were predictors of resolution of ME and better visual outcome at final follow-up.
The exact mechanisms of disruption of the ELM and EZ are still unknown.
11 What our study adds is that assessing these SD-OCT parameters at 1 month after the first IVB injection, when hemorrhages start to clear, may yield a different result than that noted at baseline. The difference in the predictive ability of the ELM and EZ at baseline and 1 month after IVB injection stems from the fact that acute photoreceptor swelling or damage and overlying hemorrhage at baseline may influence the interpretation of these SD-OCT features.
4,11 Studies have reported a definite role of anti-VEGF injections in clearing retinal hemorrhages in patients with BRVO.
4 Therefore, if we look for these structures during follow-up when the photoreceptor swelling and hemorrhage have started to resolve, we may determine a better prognostic value of these SD-OCT parameters.
1 Kang et al 1 mentioned that 8 of their patients with BRVO were excluded from the study due to nonvisualization of the ELM and EZ at baseline. They acknowledged that in such a scenario, follow-up SD-OCT after intravitreal anti-VEGF would help in identifying these structures and prove their prognostic significance. Our study has attempted to answer the same question. There has been recent interest in the prognostic significance Group A consisted of subjects with less than or equal to 25% reduction in CFT; Group B, more than 25% reduction in CFT. of FB, a novel OCT feature. Studies have reported its prognostic ability in various conditions like BRVO, retinal detachment, and amblyopia. 8, 12, 13 Hasegawa et al 8 have reported that eyes with BRVO with intact FB after resolution of ME have better visual acuity outcomes. An intact FB at final follow-up was noted to be significantly associated with dry macula and better visual outcome. Our findings are in keeping with those of Hasegawa et al. 8 Interestingly, we also noted the significance of FB visualization at 1 month after anti-VEGF injection as a good prognostic factor. A key focus of this study was the correlation between the quantitative reductions of CFT at 1 month after the first anti-VEGF injection with the final outcome. The extent of reduction in CFT at 1 month after IVB injection has not been correlated with resolution of ME and visual outcome in the past. Post hoc analysis of the Treatment of Macular Edema following Branch Retinal Vein Occlusion: Evaluation of Efficacy and Safety (BRAVO) and Treatment of Macular Edema following Central Retinal Vein Occlusion: Evaluation of Efficacy and Safety (CRUISE) studies has correlated the reduction in CFT with the visual outcomes in BRVO and CRVO, respectively. 4, 10, 14 One study analyzed the time domain OCT images at baseline and 3 months after 3 monthly injections of ranibizumab.
10 They classified the eyes with CFT of 250 µm or less at 3 months as early responders. Early responders among CRVO eyes had better visual outcome at final follow-up than the remaining eyes. Among BRVO eyes early responders had significantly better visual outcome only at 3 months. We have found that eyes with more than 25% reduction in CFT at 1 month after the first IVB injection were more likely to have dry macula and better visual outcome at final followup than eyes that had less than or equal to 25% reduction in CFT. We did not use a specific CFT value as a cut-off for comparison due to the fact that different eyes may have different CFT at baseline, depending upon the severity of ME at presentation and VEGF load. Our study suggests that the response to the first IVB injection measured at 1 month has a predictive ability for resolution of ME and visual outcome in eyes with BRVO.
In day-to-day clinical practice, there is a trend toward PRN treatment because intensive monthly injections are costly and compliance is poor. Studies have shown similar outcomes in both groups.
3 Prognostic indicators might help in stratifying patients into groups requiring intensive or PRN treatment. Our study indicates that patients having more than 25% reduction after the first injection might be good candidates for PRN treatment, whereas patients having less than 25% reduction might need intensive treatment from the beginning.
Our study has a few limitations. It was a retrospective, noncomparative case series with a limited number of subjects. To conclusively prove that the extent of CFT reduction was a strong predictor of visual outcome in BRVO patients, a prospectively designed study is required. However, our study is the first to report that the extent of CFT reduction at 1 month can be a parameter to predict the outcome of BRVO. Similarly, the present study has for the first time assessed the prognostic role of the ELM, EZ, and FB at 1 month after the first IVB injection in BRVO patients.
The finding that the integrity of the ELM, EZ layer, and FB at 1 month after IVB injection were predictors of better visual outcome will help in better understanding the value of SD-OCT parameters in BRVO patients. The role of CFT reduction after the first IVB injection as a predictor of visual outcome will help clinicians in better prognostication of eyes with BRVO.
